Fact CheckerSign in

NCT05129787Active, not recruiting

Ablation vs Resection of Colorectal Cancer Liver Metastases

A Randomized Controlled Trial of Needle Ablation With 3D Verification vs Surgical Resection of Colorectal Cancer Liver Metastases

Source: ClinicalTrials.gov · Last updated 12 Feb 2026

Brief summary (registry, in English)

230 patients with colorectal cancer liver metastases will be randomly assigned to resection or thermal ablation.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
230 (estimated)
First submitted
2 Nov 2021
Start date
16 Dec 2021
Primary completion date
23 Oct 2026
Lead sponsor
Oslo University Hospital
NCT number
NCT05129787

What you commit to

  • Study type: Interventional
  • Planned participants: 230
  • From 16 Dec 2021 to the primary completion date, 23 Oct 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Surgical indication for removal of enlarged lymph nodes in the hepatic hilum. (Enlarged lymph nodes without indication of removal are not considered an exclusion criterium)
  • Progression (as of RECIST \[18\]) on 2nd line chemotherapy
  • Previous inclusion in this trial
  • Simultaneous resection of primary tumor or any other concomitant surgical procedure

Other

  • More than 3 lung metastases where 1 is \>10mm, or 1 lung metastasis \>15 mm (OR: unresectable lung metastases as decided by the lung MDT meeting)
  • Presence of extrahepatic, extrapulmonary metastases.
  • Tumor closer than 10 mm to right/left main bile duct
  • Suspected tumor infiltration to adjacent organs
  • Not eligible for workup according to study criteria
  • Contraindication to contrast enhanced CT scan
  • Manifest liver cirrhosis
  • Pregnancy
  • ECOG performance status ≥3
  • Any other reason why, in the investigator's opinion, the patient should not be included.

Who the study is looking for

  • Histologically verified colorectal cancer
  • Colorectal liver metastases (proven or suspected) eligible for radical treatment using EITHER resection OR ablation (not a combination), as decided by the liver MDT meeting at the study center
  • The patient is fit to undergo both resection and ablation of all liver metastases
  • Size of largest lesion up to and including 30 mm
  • In case of solitary metastasis, resection plan includes resection of ≤ 2 anatomical segments.
  • In case of multiple metastases in one continuous resection, resection plan can include ≤ 4 anatomical segments (including hemihepatectomy)
  • ≤ 5 tumors to be treated in one procedure
  • Primary tumor either resected (primary first) or with a plan for curative treatment (liver first).

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Oslo University Hospital, Department of Gastrointestinal surgery, The National Hospital
Coordinator of this site? Confirm its status
OsloNorwayUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.